Title of Invention	AMPHOTROPIC RETROVIRAL PACKAGING CELL LINE AND PROCESS FOR ITS PRODUCTION
Abstract	This invention relates to a Amphotropic retroviral packaging cell line which contains functional gag, pol and env genes integrated into the genome in which the expression of the genes gag and pol is regulated independently of the expression of the env genes, wherein the genome of the said cell line contains one or two functionally active env genes.

Full Text

Amphotropic retrovirus packaging cell line, process for its production and use thereof The invention concerns an improved amphotropic retroviral packaging cell line, a process for its production as well as its use especially for gene therapy in vitro and in vivo. High virus titres can be achieved with retroviral vectors which are produced by such a packaging cell line. Retroviral vectors are widely used to transfer foreign genes into cells of mammals and humans. However, for safety reasons such retroviral vectors should no longer be replication-competent. For this reason packaging cell lines are used to produce retroviral vectors which are not able to produce wild-type virus since they contain no functional packaging sequences. Such packaging cell lines have been known and described for a long time: M/2 (Mann et al., Cell 33 (1983) 153-156), \\f-Am (Cone and Mulligan, Proc. Natl. Acad. Sci. USA 81 (1994) 6349-6353), PA12 (Miller et al., Mol. Cell Biol. 5 (1985) 431-437), GP+E-86 (Markowitz et al., J. Virol. 62 (1988) 1120-1124), PA317 (Miller and Buttimore, Mol. Cell Biol.6 (1986) 2895-2902), and GP+env Aml2 (Markowitz et al., Virology 167 (1988) 400-406), see also "Handbuch der molekularen Medizin", Vol. 1 Ed. D. Ganten and K. Ruckpaul, Springer Publishers, Heidelberg 1997, R. Ruger, chapter 2.1, 197-241. However, all these packaging cell lines except for GP+env Aml2 (referred to as Aml2 in the following) lead to a certain extent to the formation of wild-type virus (Bosselman et al., Mol.Cell Biol. 7 (1987) 1797-1804), In contrast Aml2 in which the viral gag and pot functions are introduced into the cell on one plasmid and env is introduced into the cell on another plasmid, is a safe packaging cell line. These functions are therefore integrated in different loci of the packaging cell genome. In order to form wild-type virus from Am 12 three recombinations have to occur which restore the original intact genome. This appears to be almost impossible and also has previously not been observed. In order to avoid the problems caused by homologous recombination in packaging cell lines attempts have for example also been made to express gag/pol and env by different promoters (Meyers et al., Arch.Virol. 119 (1991) 257-264; Dougherty et al, J.Virol. 63 (1989) 3209-3212) and to use packaging cell lines based on spleen necrosis virui (SNV) (Martinez and Dornburg, Virology 208 (1995) 234-241). However, a disadvantage of the known packaging cell lines is that the vector-virus titres of the retroviral vectors produced in this manner are very low and range between 10- and a maximum of 10^ colony-forming units (CFU)/ml cell culture supernatant. The object ot the invention is to provide retroviral, safe packaging cell lines which are able to produce vector viruses with a high transduction efficiency. The invenCior. concerns an amphotropic retroviral packaging cell line which contains funciional gag, pol and env genes integrated into the genome in which the expression of the genes gag and pol is regulated independently of the expression of the env genes characterized in that the genome of the said cell line contains one or two functionally active env genes. A further subiect matter of the invention is a process for producing a retroviral vector characterized in that an amphotropic retroviral packaging cell line according to the invention is transfected with a vector-virus (vector genome) which contains one or more genes that are heterologous for the virus but contains no functionallv active retroviral structural genes in "which the cell line is cultured and the retroviral vector is isolated from the culture supernatant. A further subiect matter of the invention is a process for producing an amphotropic retroviral packaging cell line characterized in that an env helper plasmid containing a selection gene and a gag/pol helper plasmid containing a selection gene are transfected into a eukaryotic cell, transfected cells are identified on the basis of the selection gene and are isolated and those cells are selected which contain one or two functionally-active env genes. A further subiect matter of the invention is a replication-incompetent retroviral vector virus which has been produced by the method according to the invention. It has turned out that the number of env integrates in the genome of a packaging cell line has a decisive influence on the transduction efficiency of the vector-viruses produced in this manner. This is all the more surprising since it is known from Martinez and Dornburg, Virology 208 (1995) 234-241 that the extent of env expression in a packaging cell line would not have an influence on the transduction efficiency. The packaging cell lines examined by Martinez and Dornburg differ with respect to env expression only in the promoter strength of the sequences regulating env expression. In a preferred embodiment the packaging cell line according to the invention contains two env integrates and a gag/pol integrate. According to the invention use of the packaging cell line achieves a titre of retroviral vectors of 2 * 10^ to 10' or 7 more, preferably at least 10 colony-forming units/ml cell culture supernatant and/or preferably a transduction efficiency of at least 50 % in MOLT-4 cells (ATCC CRL 15S2) after three days measured by the centrifugation method. The independent regulation of the gene expression of gag/poi and env is usually achieved by locating at least one expression control sequence and/or a stop signal between gag/pol and env. Starting cell lines for the packaging cell line are for example 3T3, D17. Suitable starting vectors are based on, for example, MLV, MoMuLV. Such suitable packaging cell lines and starting vectors are known to a person skilled in the art and are described for example by R. Riiger (1997) in "Handbuch der molekularen Medizin". The cell line HSR BMOl is particularly preferred as a packaging cell line according to the invention. This cell line was deposited on 12.09.1995 by Boehringer Mannheim GmbH according to the Budapest Contract in the "Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH" (DSM), Mascheroder Weg lb. 38124 Braunschweig under the No. DSM ACC 2235. A further subject matter of the invention is a process for producing an amphotropic retroviral packaging cell line according to the invention. An amphotropic split genome retroviral packaging cell line can for example be produced as described in Markowitz et al, Virology 167 (1988) 400-406. Two plasmids are used for this w^hich code for the so-called f helper sequences (gag, pol and env). In order to select cell lines according to the invention, the number of env and gag/pol integrates has to be determined. This is expediently carried out by digesting the genomic DNA with restriction enzymes which do not cleave in the gag/pol sequences or env sequences and determining the number of fragments which contain gag/pol- or env-specific sequences. The invention whose protective scope results from the patent claims is further elucidated by the following examples and publications. The described methods are to be understood as examples which still describe the subject matter of the invention even after modifications. Example 1 Construction of helper plasmid^ Construction of the gag/pol helper plasmid: A helper plasmid carries the viral structural genes gag/pol of the Moloney murine leukaemia virus (MoMULV) e.g. under the control of the MoMULV 5'LTR. These structural genes gag/pol together with the 5*LTR can be obtained from the proviral DNA of MoMULV by restriction digestion. In this process it is important for safety reasons to inactivate the so-called packaging sequences \\f. This can for example be achieved by a deletion which is introduced with the aid of a restriction digestion. Furthermore it is advantageous to have a selectable marker such as e.g. the gpt gene on the helper plasmid the gene product of which imparts resistance to the selection drug mycophenolic acid. Mycophenolic acid resistance allows the rapid selection of clones which have taken up the desired plasmid (gag/pol helper plasmid). A corresponding helper plasmid can be constructed as described for example by Markowitz et al, J. ViroL 62 (1988) 1120-1124. Construction of the env helper plasmid: Another helper plasmid carries the viral structural gene env of the amphotropic murine leukaemia virus clone 4070A (4070A) (Chattopadhyay et al., J. Virol. 39 (1981) 777-791) e.g. under the control of MoMULV 5'LTR. For this a fragment of the proviral DNA of 4070A which contains the env gene and the 3' acceptor splice site is isolated. This fragment is cloned into a plasmid which contains the MoMULV 5'LTR as well as the 5' donor splice site. A corresponding helper plasmid can be produced as described for example by Markowitz et al., Virology 167 (1988) 400-406. Example 2 Transfer of the helper constructs Transfer of the gag/pol helper plasmid: NIH 3T3 cells (ATCC No. CRL 1658) are for example firstly transfected with the gag/pol helper plasmid. This can for example be carried out with the aid of electroporation. Transfected cells can be isolated with the aid of a suitable selection medium since the gpt gene is present on the gag/pol plasmid. A suitable selection medium contains for example hypoxanthine (15 |ig/ml), xanthine (250 |ig/ml) and mycophenolic acid (25 |ig/ml) (HXM medium). Resistant clones can be subsequently examined for the expression of reverse transcriptase (RT) as for example described by Markowitz et al., J.Virol 62 (1988) 1120-1124. A clone that expresses to a particularly high degree is selected for subsequent transfection with the env helper plasmid. Transfer of the env helper plasmid: Subsequently the env helper plasmid can be transfected for example with the aid of electroporation into a gag/pol-transfected, mycophenolic acid-resistant clone with high RT activit>\ In order to simply identify successfully transfected cells it is advantageous to for example co-transfect a further plasmid which contains a resistant gene together with the helper plasmid. This can for example be a plasmid which imparts resistance to hygromycin such as for example the plasmid pRSHhyg (Murphy, A.J. (1987) doctoral thesis, Columbia University, USA). Successfully transfected clones can be simply selected with the aid of a suitable selection medium which for example contains 200 fxg/ml hygromycin B. Hygromycin-resistant clones can be subsequently examined for env expression with the aid of radioimmuno-precipitation using an env antiserum as for example described in Markowitz et al., Virology 167 (1988) 400-406. Example 3 Selection of amphotropic retroviral packaging cell lines The number of copies of the env helper plasmid integrated into the genome was selected as a parameter for choosing a certain subclone of a packaging cell line. Martinez and Dornburg, Virology 208 (1995) 234-241 have showed that, in contrast to gag/pol, a higher env expression has no influence on the virus titre; the titre of clones with a higher gag/pol but not a higher env expression correlated with the found infection efficiency. This was the basis for the assumption that the ratio of gag/pol to env gene products may be very important for the efficiency of packaging cells and possibly packaging cells with a lower env expression may lead to viral supernatants with a higher transduction efficiency. Determination of the number of env integrates: The number of copies of the env helper plasmid integrated into the genome of the individually examined clones was determined with the aid of restriction digestion and Southern blot analysis. For this genomic DNA was isolated from various subclones and digested with the aid of restriction enzymes e.g. the enzyme PstI. This enzyme does not cleave in the env sequence and only cleaves once in the entire plasmid sequence. Since each corresponding second cleavage site which leads to the respective restriction fragment is located randomly in the genome, it is possible in this manner to determine the number of env integrates. The digested DNA was separated in an Agarose gel and transferred onto a nylon membrane by means of capillary transfer. The fragments which contain env-specific sequences were detected with the aid of an env-specific, digoxigenin-labelled DNA probe. Subclones with different numbers of env integrates were found. For example the band sizes that were obtained after digestion with the restriction enzyme PstI were 17.5 kb, 13.3 kb and 3.4 kb for the packaging cell line GP+env Aml2 and 13.3 kb and 3.4 kb for the packaging cell line HSR BMOl. Example 4 Production of virus-producing cell lines with different numbers of env integrates Each subclone was transfected either with two (HSR BMOl) or three (GP+env Aml2) env intesjrates containing the retroviral construct pLl in order to produce virus-producing cell lines (producer lines). The construct pLl carries the cDNA for a shortened form of the human low affinity nerve growth factor receptor (hA LNGFR (produced analogously to WO 95/06723)) in which the cytoplasmic domain is deleted and which is under the control of the viral 5' LTR. The gene product of the hALNGFR cDNA, a membrane protein, can be detected on the cells with the aid of a hALNGFR-specific monoclonal antibody (mAb). Virus-producing clones were isolated from HSR BMOl (HSRBM-Ll) as well as from GP+env Aml2 (clone C11-C4) with the aid of immunofluorescence and flow cytometry. Determination of the titre of supernatants from virus-producing cells containing different numbers of env integrates: Indicator cells (NIH/3T3; ATCC No. CRL 1658) were transduced with the supernatants containing virus particles from the two clones HSRBM-Ll or Cll-C4. A cytochemical staining method based on the anti-hALNGFR mAb allows the determination of the number of colony-forming units (titre) of hALNGFR-coding retroviruses. Whereas the supernatant of the producer line C11-C4 (3 env copies) based on the packaging cell GP+env Am 12 had a titre of 6.3 x 10^ colony-forming units, the supernatant of the producer line HSRBM-Ll (two env copies) based on HSR BMOl had a titre of 1.25 x 10^. Example 5 Transduction of various cell lines with supernatants from two different producer cell lines which contain the same retroviral vector The cell lines Jurkat, MOLT4, Raji and K 562 are cultured in RPMI/10 % FCS under normal cell culture conditions and transduced at cell densities of 3-9 x 10^ cells/ml. The various producer cell lines which contain an identical retroviral vector are cultured in DMEM/10 % FCS under normal cell culture conditions. The cells are seeded at 1 x 10^ cells/cm^. After three days the supernatant is discarded and fresh medium is added. The supernatant is harvested 24 hours later. The supernatant is filtered through a 0.22 pm filter. The titre of the various supernatants is determined and adjusted such that equivalent volume amounts contain an equivalent number of virus particles. The titre of the retroviral supernatant was determined using the method of immune staining titration using NIH3T3 as target cells. Transduction Protocol 1: 5 X 10^ cells are resuspended in 1 ml retroviral supernatant. Th*? transduction is carried out in a 24-well plate. After centrifugation (1000 g, 30°C, 90 min.) the cells are washed and resuspended in 1 ml fresh cell culture medium. The cells are incubated overnight and 1 ml fresh medium is added. Three days after transduction the cells are harvested and stained with an FITC-labelled anti-LNGFR antibody. The percentage of LNGFR-expressing cells is determined by means of flow cytometry. In this process dead cells are excluded from the analysis by propidium iodide staining. The flow-cytometry analysis is carried out on a FACScan instrument. Protocol 2: The procedure in protocol 2 was carried out according to protocol 1, but without centrifugation. The cells are incubated for two hours at 37°C with the retroviral supernatant. Table 1 shows the LNGFR expression of various cell lines three days after transduction according to protocol 1. Table 2 shows the LNGFR expression of various cell lines three days after transduction according to protocol 2. Table 2 % LNGFR-positive cells three days after transduction (incubation method) List of References Bosselman et al, Mol. Cell Biol 7 (1987) 1797-1804 Chattopadhyay et al, J. Virol. 39 (1981) 777-791 Cone and Mulligan, Proc. Natl. Acad. Sci. USA 81 (1994) 6349-6353 Dougherty et al., J. Virol. 63 (1989) 3209-3212 Handbuch der molekularen Medizin, Volume I, Ed. D. Ganten and K. Ruckpaul, Springer Verlag Heidelberg 1997, R. Ruger, Chapter 2.1, 197 - 241 Mann et al. Cell 33 (1983) 153-156 Markowitz et al., J. Virol. 62 (1988) 1120-1124 Markowitz et al.. Virology 167 (1988) 400-406 Martinez and Dornburg, Virology 208 (1995) 234-241 Meyers et al., Arch. Virol. 119 (1991) 257-264 Miller and Buttimore, Mol. Cell Biol. 6 (1986) 2895-2902 Miller et al, Mol. Cell Biol. 5 (1985) 431-437 Murphy, A.J. (1987), Doctoral Thesis, Columbia University, USA Patent Claims Amphotropic retroviral packaging cell line which contains functional gag, pol and env genes integrated into the genome in which the expression of the genes gag and pol is regulated independently of the expression of the env genes, wherein the genome of the said cell line contains one or two functionally active env genes. Packaging cell line as claimed in claim 1, wherein it contains two env integrates and one gag/pol integrate. Packaging cell line as claimed in claims 1 or 2, wherein a titre of at least 2 X 10" to 10 colony-forming units/ml cell culture supernatant is achieved when packaging a retroviral vector. Process for producing an amphotropic retroviral packaging cell line, wherein an env helper plasmid containing a selection gene and a gag/pol helper plasmid containing a selection gene are transfected into a eukaryotic cell, transfected cells are identified on the basis of the selection gene and are isolated and those cells are selected which contain one or two functionally-active env genes. Packaging cell line DSM ACC 2235. Process for the production of a retroviral vector, wherein a packaging cell line as claimed in claims 1 - 3 is transfected with a vector genome which contains one or more heterologous genes for the virus but contains no functionally active retroviral structural genes, the cell line is cultured and the retroviral vector is isolated from the culture supernatant. Replication-incompetent retroviral vector-virus obtained by a process as claimed in claim 6. Patent Claims Amphotropic retroviral packaging cell line which contains functional gag, pol and env genes integrated into the genome in which the expression of the genes gag and pol is regulated independently of the expression of the env genes, wherein the genome of the said cell line contains one or two functionally active env genes. Packaging cell line as claimed in claim 1, wherein it contains two env integrates and one gag/pol integrate. Packaging cell line as claimed in claims 1 or 2, wherein a titre of at least 2 X 10" to 10 colony-forming units/ml cell culture supernatant is achieved when packaging a retroviral vector. Process for producing an amphotropic retroviral packaging cell line, wherein an env helper plasmid containing a selection gene and a gag/pol helper plasmid containing a selection gene are transfected into a eukaryotic cell, transfected cells are identified on the basis of the selection gene and are isolated and those cells are selected which contain one or two functionally-active env genes. Packaging cell line DSM ACC 2235. Process for the production of a retroviral vector, wherein a packaging cell line as claimed in claims 1 - 3 is transfected with a vector genome which contains one or more heterologous genes for the virus but contains no functionally active retroviral structural genes, the cell line is cultured and the retroviral vector is isolated from the culture supernatant. Replication-incompetent retroviral vector-virus obtained by a process as claimed in claim 6.

Documents:

IN-PCT-2000-676-CHE AMANDED CLAIMS 24-11-2009.pdf

IN-PCT-2000-676-CHE AMANDED PAGES OF SPECIFICATION 24-11-2009.pdf

IN-PCT-2000-676-CHE CORRESPONDENCE OTHERS 07-09-2009.pdf

IN-PCT-2000-676-CHE EXAMINATION REPORT REPLY RECIEVED 24-11-2009.pdf

IN-PCT-2000-676-CHE FORM-3 24-11-2009.pdf

IN-PCT-2000-676-CHE OTHER DOCUMENT 07-09-2009.pdf

IN-PCT-2000-676-CHE POWER OF ATTORNEY 24-11-2009.pdf

in-pct-2000-676-che-claims.pdf

in-pct-2000-676-che-correspondence others.pdf

in-pct-2000-676-che-correspondence po.pdf

in-pct-2000-676-che-description complete.pdf

in-pct-2000-676-che-form 1.pdf

in-pct-2000-676-che-form 19.pdf

in-pct-2000-676-che-form 26.pdf

in-pct-2000-676-che-form 3.pdf

in-pct-2000-676-che-form 5.pdf

in-pct-2000-676-che-pct.pdf

IN-PCT-2001-676-CHE FORM-3 10-12 -2009.pdf

IN-PCT-2001-676-CHE OTHER PATENT DOCUMENT 10-12 -2009.pdf